Showing 128 Results
NPC’s John O’Brien Talks IRA, Drug Pricing, Patient Costs & Access on The Real Chemistry Podcast
In the latest episode of The Real Chemistry Podcast, NPC President and CEO John M. O'Brien spoke with Real Chemistry’s Founder and Chairman, Jim Weiss, on pressing health policy issues.
NPC Evaluates ICER’s Revised 2023 Value Assessment Framework: A Missed Opportunity for Patients and the Field
The Institute for Clinical and Economic Review (ICER) released its revised value assessment framework. NPC outlines key concerns about the framework and the impact on both patients and those who…
Addressing Critical Ambiguities in CMS’s Drug Evaluation Process
With CMS's release of the list of drugs selected for evaluation under the IRA's Medicare Drug Price Negotiation Program, all eyes turn from the list to what’s next in the process. In this blog, NPC's…
Getting Patient Input Right During the IRA Implementation
Important questions remain on how patient input will be incorporated in the IRA process as we approach the release of the list of drugs selected for negotiation.
In 2023, Decision Makers Should Dig into Data About Our Drug Pricing System
In Chain Drug Review, NPC's John O'Brien discusses how 2023 brings renewed imperative to root health policy decisions in evidence.
Shared Decision-Making Makes Sense for Patients and the Bottom Line
If shared decision-making is good for patients, is it good for the bottom line as well? A new study from NPC and Real Chemistry sheds light.
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
Commentary: "New York Times Piece on Drug Market Ignores the Data (and Reality)"
NPC's President and CEO John M. O'Brien addresses research using politically expedient shortcuts and the consequences on policy...and patients.
NPC Creates Guiding Principles for Designing and Evaluating Health Care Spending Research and Policies
NPC has developed principles to help evaluate health spending research.
New Moves to Shine More Light Into an Opaque Drug Pricing System
In his latest column for Chain Drug Review, NPC President and CEO John M. O’Brien points to the need for greater transparency in the pharmacy benefit manager-led rebate system.
Drug Price Regulation Trade-offs: Real or Imagined?
NPC hosted a panel at AcademyHealth’s National Health Policy Conference to explore the potential risks and unintended consequences of drug price regulation.
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and continued…
NPC in Chain Drug Review: Fostering a More Informed Drug Pricing Conversation
To kick off the new year, NPC's John M. O’Brien writes in Chain Drug Review about the need for a more informed public discussion about the role that prescription drugs play in our health care system…
NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients
In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…
Drug Spending Mirrors Spending on Other Health Care Services
Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are disregarding…
Health Care Stakeholders Can Learn from Pharmacists’ Patient-Centered Perspective
In a commentary for Pharmacy Times, NPC's John M. O’Brien describes the commitment of pharmacists to ensuring patient access to needed medicines and says other health care stakeholders should follow…
Reference Pricing Isn’t Worth the Risk to Innovation and Patient Health
A Health Affairs Blog co-authored by NPC's Michael Ciarametaro explores the tradeoffs and risks associated with international reference pricing and suggests alternative policy approaches that would…
NPC in Health Affairs: Payment Innovation Not Keeping Up
In a Health Affairs Blog article, NPC and MIT researchers outline how a new rule from CMS may fall short of what is needed to improve patient access to durable cell and gene therapies that target…